Expertise in molecular biology, neuroscience, and genetics in psychedelics

Darryl has deep expertise in molecular biology, neuroscience, and genetics in psychedelics. He holds a PhD in molecular biology and genetics. GoodCap Pharmaceuticals Inc. ( is a leading Canadian drug development company devoted to harnessing and applying the physical and mental health benefits of mushrooms and mushroom-derived compounds. GoodCap is a leader in formulation, research and development of psilocybin-based therapeutic products and is dedicated to discovering natural therapies for inflammatory disorders and mental health conditions.  Prior to founding GoodCap, Darryl co-founded InPlanta Biotechnology Inc. and Pathways Rx, where he led the development and commercialization of proprietary plant genetics in the Cannabis industry. He has also co-authored numerous peer-reviewed research articles on plant biology, genetics, DNA repair, epigenetics, and cancer.